Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:17 PM
Ignite Modification Date:
2025-12-24 @ 3:17 PM
NCT ID:
NCT03881592
Eligibility Criteria:
Inclusion Criteria:
* Diagnosis of Chronic Lymphocytic Leukemia
* Patients treated with Bendamustin plus Rituximab, Rituximab plus Chlorambucil or Obinutuzumab plus Chlorambucil regimens as first line of treatment
* Provision of informed consent for recording of patient data in the CLLEAR registry
Exclusion Criteria:
* All untreated patients
* Patients with both Rituximab plus Chlorambucil and Bendamustin plus Rituximab or Obinutuzumab plus Chlorambucil in second or subsequent lines
* Patients with prednisone alongside analysed regimens in the first line of treatment
* Patients with RCD (Rituximab, Cyclophosphamide, Dexamethasone) or FCR (Fludarabine, Cyclophosphamide, Rituximab) or other regimen before analysed regimens within the first line of treatment
* Patients with R-Dex (Rituximab and Dexamethasone) cycles in between R-Clb cycles
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT03881592
Study Brief:
Protocol Section:
NCT03881592